Indus Pharma Private Limited - Due diligence report

A 360° intelligence report on Indus Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and di…

1987-01-12 New Delhi, Delhi Active Unlisted Active Compliant
Share
IP Indus Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Indus Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Indus Pharma Private Limited is assessed as Low Risk with a Trust Score of 88/100. Indus Pharma Private Limited is an active private limited indian non-government company incorporated in 1987, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Indus Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
73/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (B+).

Charges position: 2 open (12.00 cr) · 11 satisfied (20.57 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others3 48.0 cr
Sidbi2 48.0 cr
Union Bank Of India7 48.0 cr
Union Bank Od India1 48.0 cr
Compliance Score: 73/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (4 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RADHEY SHYAM ARORA 01234567 Director 01/04/2018 6 yrs Approved
SURINDER ARORA 01234567 Director 01/04/2018 6 yrs Approved
MUKTA ARORA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: RADHEY SHYAM ARORA (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Net margin improved to 0.86.
Operating for 39+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
2 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 7.73 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 12.00 cr already registered.
  • Compliance record supports lending.
Investor view89/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
05 Dec 2020
Charge satisfied
Others
04 Dec 2020
Charge satisfied
Sidbi
21 Sep 2020
Charge created
Others - 6.00 cr
26 Sep 2018
Charge created
Others - 4.25 cr
21 Aug 2018
Charge satisfied
Sidbi
25 Jan 2017
Securities allotted
89507 Equity Shares - 8.95 Lakh raised
12 Jan 2017
Charge created
Sidbi - 3.25 cr
Charge created
Sidbi - 7.70 cr
09 Jan 2017
Charge satisfied
Union Bank Of India
Charge satisfied
Union Bank Od India
15 Jun 2016
Director appointed
SURINDER ARORA (Director)
Director appointed
MUKTA ARORA (Director)
Director ceased
SURINDER KUMAR
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Puratos Food Ingredients India Private Limited U15400MH1996PTC102629 Mumbai, Maharashtra, India
Nalinam Enterprises Private Limited U51909TZ2020PTC033289 Salem, Tamil Nadu, India
Bhaskar Resins Private Limited U25200MP2012PTC029490 Indore, Madhya Pradesh, India
Karishma Computers Private Limited U72900DL1996PTC077144 New Delhi, Delhi, India
Mehta Tea Private Limited U51226MP1998PTC012919 Indore, Madhya Pradesh, India
S L Saraf Impex Private Limited U51909DL2003PTC121853 New Delhi, Delhi, India
Six O Tu Investments And Traders Private Limited U51900MH1982PTC028329 Lower Parel, Maharashtra, India
Jaibaba Motors Private Limited U66000WB2015PTC206387 Paschim Medinipur, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Indus Pharma Private Limited before audits and certifications: compliance score 73/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Indus Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Indus Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Indus Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Indus Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Indus Pharma Private Limited an active company?

Indus Pharma Private Limited has MCA status “Active” with a compliance score of 73/100 (Moderate).

Is Indus Pharma Private Limited financially healthy?

Indus Pharma Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Indus Pharma Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Indus Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Indus Pharma Private Limited have loans or charges against its assets?

2 open charge(s) are registered against its assets, and 11 earlier charge(s) stand satisfied.

Is Indus Pharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 73/100 (Moderate).

Is it risky to lend to Indus Pharma Private Limited?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.